Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

NCT06041646 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT06041646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 4
Overall status
Completed
Start date
October 2, 2023
Completion date
April 29, 2024
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

agitation,psychomotor, bipolar disorder, schizo affective disorder, schizophrenia, schizophreniform disorders